Related Experiment Video
Updated: Jun 17, 2026
05:14
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Treating schizophrenia: novel targets for the cholinergic system.
T T Money1, E Scarr, M Udawela
1the Mental Health Research Institute, Parkville, Victoria, Australia.
CNS & Neurological Disorders Drug Targets
|January 8, 2010
Summary
Schizophrenia cognitive deficits may stem from underactive cholinoceptors. Targeting these receptors with new drugs offers a promising therapeutic avenue for improving cognitive function in patients.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cognitive deficits in schizophrenia are a major challenge, largely unresponsive to current treatments.
- Cholinergic receptors (nicotinic and muscarinic) play a crucial role in cognitive function.
- Acetylcholinesterase inhibitors show potential in reducing schizophrenia-related cognitive deficits, suggesting cholinoceptor under-stimulation.
Purpose of the Study:
- To review the involvement of cholinoceptors in schizophrenia pathophysiology.
- To explore how this understanding can inform targeted therapeutic strategies.
- To highlight novel approaches for treating cognitive deficits and psychosis in schizophrenia.
Main Methods:
- Review of current scientific literature and evidence.
- Analysis of the role of cholinoceptors in cognitive function and schizophrenia.
- Examination of therapeutic strategies targeting cholinergic pathways.
Main Results:
- Cholinergic pathways are implicated in the pathophysiology of schizophrenia's cognitive deficits.
- Muscarinic receptors are involved in dopamine modulation, offering a potential target for psychosis treatment.
- Development of receptor agonists and allosteric modulators is a key focus for therapeutic intervention.
Conclusions:
- Cholinergic system modulation presents a promising strategy for treating cognitive deficits in schizophrenia.
- Targeting specific cholinoceptors offers a pathway for developing more effective and targeted therapies.
- Further research into cholinoceptor function could lead to novel treatments for both cognitive and psychotic symptoms.
More Related Videos
07:30HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:28Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...